Literature DB >> 28500107

Metastatic Breast Cancer.

Olive Peart.   

Abstract

Despite advances in breast cancer screening, diagnosis, and treatment, nearly 12% of patients with a diagnosis of breast cancer eventually develop metastatic disease, or breast cancer that has spread beyond the breast to other parts of the body. No cure for metastatic breast cancer yet exists, and it is associated with a poor prognosis: The 5-year survival rate is 26%. Nevertheless, many treatments can improve and extend the lives of patients with metastatic breast cancer. This article reviews the types of breast cancer and cancer staging systems. It also discusses the molecular subtypes of breast cancer, symptoms of metastatic breast cancer, and current treatments for the disease. ©2017 American Society of Radiologic Technologists.

Entities:  

Mesh:

Year:  2017        PMID: 28500107

Source DB:  PubMed          Journal:  Radiol Technol        ISSN: 0033-8397


  49 in total

1.  Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE.

Authors:  Silvana Leo; Ermenegildo Arnoldi; Lazzaro Repetto; Zaira Coccorullo; Saverio Cinieri; Palma Fedele; Marina Cazzaniga; Vito Lorusso; Agnese Latorre; Giovanna Campanella; Mariangela Ciccarese; Caterina Accettura; Salvatore Pisconti; Antonio Rinaldi; Cosimo Brunetti; Mimma Raffaele; Luigi Coltelli; Salvatore Spazzapan; Lucia Fratino; Luciana Petrucelli; Laura Biganzoli
Journal:  Oncologist       Date:  2018-11-09

2.  miR-638 represses the stem cell characteristics of breast cancer cells by targeting E2F2.

Authors:  Qiu-Yan Lin; Jia-Qi Wang; Li-Li Wu; Wei-E Zheng; Pei-Rui Chen
Journal:  Breast Cancer       Date:  2019-08-13       Impact factor: 4.239

3.  TRG16, targeted by miR-765, inhibits breast cancer stem cell-like properties via regulating the NF-κB pathway.

Authors:  Feng Chi; Xiaoming Jin; Long Chen; Guijin He; Sijia Han
Journal:  Mol Cell Biochem       Date:  2022-06-01       Impact factor: 3.396

4.  Muslim Women and Disparities in Cancer Diagnosis: A Retrospective Study.

Authors:  Asmaa Namoos; Nour Eldin Abosamak; Maryam Abdelkarim; Rana Ramadan; Briona Philips; Dina Ramadan; Mostafa Abdou; Tamas S Gal
Journal:  J Muslim Minor Aff       Date:  2021-12-08

Review 5.  Drug Delivery of Natural Products Through Nanocarriers for Effective Breast Cancer Therapy: A Comprehensive Review of Literature.

Authors:  Kah Min Yap; Mahendran Sekar; Shivkanya Fuloria; Yuan Seng Wu; Siew Hua Gan; Nur Najihah Izzati Mat Rani; Vetriselvan Subramaniyan; Chandrakant Kokare; Pei Teng Lum; M Yasmin Begum; Shankar Mani; Dhanalekshmi Unnikrishnan Meenakshi; Kathiresan V Sathasivam; Neeraj Kumar Fuloria
Journal:  Int J Nanomedicine       Date:  2021-12-02

6.  Benefit of home parenteral nutrition (HPN) and chemotherapy in patients with invasive lobular carcinoma developed peritoneal metastases.

Authors:  Masayuki Inoue; Ayako Kimura; Tomomi Oka; Aya Yajima; Yudai Higuchi; Tatsuki Endo; Hideki Watanabe; Hiroshi Nakagomi
Journal:  Int Cancer Conf J       Date:  2022-03-01

7.  Circ_0008717 Sponges miR-326 to Elevate GATA6 Expression to Promote Breast Cancer Tumorigenicity.

Authors:  Ling Yang; Yuxin Chen
Journal:  Biochem Genet       Date:  2022-08-24       Impact factor: 2.220

8.  Silencing of Nek2 suppresses the proliferation, migration and invasion and induces apoptosis of breast cancer cells by regulating ERK/MAPK signaling.

Authors:  Zeyu Xing; Menglu Zhang; Xin Wang; Jiaqi Liu; Gang Liu; Kexin Feng; Xiang Wang
Journal:  J Mol Histol       Date:  2021-05-19       Impact factor: 2.611

9.  Correlation of microRNA-367 in the clinicopathologic features and prognosis of breast cancer patients.

Authors:  Binghui Liu; Juhua Pan; Chenglin Fu
Journal:  Medicine (Baltimore)       Date:  2021-06-04       Impact factor: 1.817

Review 10.  Preclinical Advances in Theranostics for the Different Molecular Subtypes of Breast Cancer.

Authors:  Hanyi Fang; Alessandra Cavaliere; Ziqi Li; Yiyun Huang; Bernadette Marquez-Nostra
Journal:  Front Pharmacol       Date:  2021-04-27       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.